Lumos Pharma, Inc. (LUMO)
NASDAQ: LUMO · IEX Real-Time Price · USD
1.460
+0.010 (0.69%)
At close: Jul 19, 2024, 4:00 PM
1.430
-0.030 (-2.05%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Lumos Pharma Revenue
Lumos Pharma had revenue of $1.53M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $165.00K. In the year 2023, Lumos Pharma had annual revenue of $2.05M with 34.67% growth.
Revenue (ttm)
$1.53M
Revenue Growth
-27.48%
P/S Ratio
7.77
Revenue / Employee
$46,212
Employees
33
Market Cap
11.85M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.05M | 528.00K | 34.67% |
Dec 31, 2022 | 1.52M | 1.29M | 562.17% |
Dec 31, 2021 | 230.00K | 62.00K | 36.90% |
Dec 31, 2020 | 168.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 12.47M | -16.24M | -56.55% |
Dec 31, 2017 | 28.71M | -7.06M | -19.73% |
Dec 31, 2016 | 35.77M | -32.73M | -47.78% |
Dec 31, 2015 | 68.50M | -104.09M | -60.31% |
Dec 31, 2014 | 172.59M | 171.50M | 15,690.67% |
Dec 31, 2013 | 1.09M | -594.00K | -35.21% |
Dec 31, 2012 | 1.69M | -185.00K | -9.88% |
Dec 31, 2011 | 1.87M | -207.00K | -9.96% |
Dec 31, 2010 | 2.08M | 1.15M | 122.59% |
Dec 31, 2009 | 934.00K | 301.00K | 47.55% |
Dec 31, 2008 | 633.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLUMO News
- 2 months ago - Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 - GlobeNewsWire
- 2 months ago - Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024 - GlobeNewsWire
- 3 months ago - Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings - GlobeNewsWire
- 4 months ago - Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 - GlobeNewsWire
- 4 months ago - Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update - GlobeNewsWire
- 5 months ago - Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024 - GlobeNewsWire
- 5 months ago - Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire